זיפרסידון

Ziprasidone is classified as Mixed 5-HT2A/D2 receptor antagonist with 5-HT1A partial-agonism; weak serotonin–norepinephrine reuptake inhibition. It belongs to the Benzisothiazolyl piperazine; second-generation (atypical) antipsychotic chemical class.

Also known as: Geodon

Classification

Chemical: Medicine

Effects

Restlessness
Akathisia Like Movement
Drowsiness
Emotional Blunting
Anxiety Suppression
Sadness
Euphoria

Routes of Administration

Oral

Dosage

Heavy: 120+ mg
Light: 10 mg - 40 mg
Common: 40 mg - 80 mg
Strong: 80 mg - 120 mg
Threshold: 10 mg

Duration

Onset: 1-3 h
Peak: 3-6 h
Offset: 6-10 h
After Effects: 10-24 h
Total Duration: 6-12 h

Intramuscular

Dosage

Heavy: 40+ mg
Light: 5 mg - 10 mg
Common: 10 mg - 20 mg
Strong: 20 mg - 40 mg
Threshold: 5 mg

Duration

Onset: 0.25-0.5 h
Peak: 0.5-1.5 h
Offset: 3-6 h
After Effects: 6-18 h
Total Duration: 4-10 h

Harm Reduction

Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.

Sources

Substance data is aggregated from the following public harm-reduction and reference sources.

openFDA.gov

Links

This static page is intended as a readable non-JS and prerender-friendly library export.

Get the full DrugsPRO experience

Open the interactive DrugsPRO app for search, saved items, interactions, and deeper harm reduction tools.

Get the PRO test kit. The simple, quick and reliable drug checking test kit. Visit https://protestkit.eu